Key result
Digitalis therapy optimization in heart failure and atrial fibrillation requires balancing conflicting evidence regarding the efficacy and safety of digoxin.
Why the study?
Does digoxin therapy improve outcomes in patients with heart failure in sinus rhythm and atrial fibrillation?
Does digoxin therapy improve outcomes in patients with heart failure in sinus rhythm and atrial fibrillation?
This review provides an overview of the mechanisms, pharmacokinetics, and optimization of digitalis therapy in patients with heart failure, addressing conflicting evidence regarding its efficacy and safety.
Advise individualized caution with digoxin in HF and AF; leaves open optimal strategies pending definitive trials.
In recent years there has been a marked decrease in cardiac glycosides use in patients with heart failure in sinus rhythm and atrial fibrillation. The results of published studies contradict each other. Some of them doubt the favorable effect of digoxin in patients with heart failure; others refute the increase in the lethality and frequency of hospitalizations associated with the use of digoxin. In this regard, we found it important to analyze these reports impartially and reflect modern views on the mechanisms of cardiac glycosides, the pharmacokinetics and the possibility of optimizing digitalis therapy in cardiac practice.
No takes yet. Share an insight, caveat, or question.
Dyadyk et al. (2018) conducted a review in Heart failure and atrial fibrillation. Digitalis therapy (digoxin) was evaluated. Digitalis therapy optimization in heart failure and atrial fibrillation requires balancing conflicting evidence regarding the efficacy and safety of digoxin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: